Condition 1: Chronic Renal Failure. Condition 2: Sleep disturbance. End-stage renal disease Nonorganic sleep disorders
Conditions
Interventions
Intervention 1: Tab melatonin 3mg/day. every night at 8 pm for 6 weeks. Intervention 2: Tab placebo(melatonin placebo). every night at 8 pm for 6 weeks.
Treatment - Drugs
Tab melatonin 3mg/day. every night at 8 pm for 6 weeks.
Tab placebo(melatonin placebo). every night at 8 pm for 6 weeks.
Sponsors
Office of Vice Chancellor for Research of Arak Medical Science University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: ESRD patients undergoing hemodialysis >3 months with PSQI score equal or >5/ age:18-85/capable of giving informed consent exclusion: severe allergy to melatonin/unstable angina or hearth failure class 4/ pregnancy or breast feeding/ severe medical or psychological disease/history of melatonin consumption
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep quality. Timepoint: Before intervention and 6th and 12th week of intervention. Method of measurement: PSQI questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum lipids. Timepoint: At study beginning, 6 and 12 weeks. Method of measurement: Valiasr lab.;Erythropoitin dosages. Timepoint: 0, 6th and 12th weeks. Method of measurement: Providing from dialysis sheets review.;Serum hemoglobin levels. Timepoint: 0, 6th and 12th weeks. Method of measurement: Valiasr lab. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Tahereh Hossein-tabar
Arak University of Medical Sciences
Outcome results
None listed